Company Profile
Supernus Stock Price, News & Analysis
Company overview
Business overview
Supernus is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Supernus is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Supernus follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Supernus sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
SUPN is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Supernus’s catalysts are Qelbree, Oxtellar, and continued CNS-franchise execution, plus any pipeline update that broadens the story. The company improves when the commercial base keeps scaling.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Supernus Announces Third Quarter 2025 Financial Results
Source: Supernus
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.